EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Five‐Year Follow‐Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon

Vladimir Sanchez Linares iD, Vicente Eloy Fardales Macías iD, Iraldo Bello Rivero iD

Journal of Skin Cancer · 2026-01 · 2026 (1)

DOI: 10.1155/jskc/8852284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Skin Cancer, online erschienen am 29.06.2026. Verfasst von Vladimir Sanchez Linares und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Medical Sciences of Sancti Spíritus, Circunvalación s/n, Sancti Spíritus, Cuba. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Basal cell carcinomas (BCCs) with aggressive histology are infiltrative, destructive, aggressive, and metastatic tumors. Aggressive variants include morpheaform, infiltrative, metatypical or basosquamous, micronodular, and mixed subtypes. Selecting the appropriate treatment is crucial to eliminate this type of tumor and avoid complications such as mutilation and deformities when located in the facial region, as well as tumor recurrence. Interferons may represent a therapeutic option because of their curative potential and long‐term cosmetic effects. Material and Methods A descriptive, longitudinal, observational case‐series study was conducted, including patients with a histopathological diagnosis of aggressive BCC. Perilesional HeberFERON was administered for three weeks, and patients were then followed for 5 years. The main outcome variables were cure at 16 weeks and recurrence at 5 years.

Results

Twenty‐three patients were included, and one discontinued treatment. After therapy, 14 (63.6%) patients achieved cure (complete response [CR]). Those who did not achieve a CR underwent surgery and were declared cured. All 22 patients were followed for five years; two (9.0%) were lost to follow‐up. Survival analysis showed that 86.4% (95% CI, 74%–99%) had the probability of remaining recurrence‐free at five years.

Conclusions

HeberFERON can be considered a first‐line treatment for BCC with aggressive histology and as a therapy prior to subsequent surgery.

Schlagwörter

Stichwörter der Autor:innen

aggressive histologybasal cell carcinomainterferonstumor recurrence

Autor:innen und Institutionen

  • University of Medical Sciences of Sancti Spíritus, Circunvalación s/n, Sancti Spíritus, Cuba.
  • Center for Genetic Engineering and Biotechnology, Havana, Cuba, cigb.edu.cu.

ORCID-Profile: Vladimir Sanchez Linares, Vicente Eloy Fardales Macías, Iraldo Bello Rivero

Zitieren

APA

Linares, V. S., Macías, V. E. F., & Rivero, I. B. (2026). Five‐Year Follow‐Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon. Journal of Skin Cancer, 2026(1). https://doi.org/10.1155/jskc/8852284

Vancouver

Linares VS, Macías VEF, Rivero IB. Five‐Year Follow‐Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon. Journal of Skin Cancer. 2026;2026(1). doi:10.1155/jskc/8852284

BibTeX
@article{Linares2026,
  author = {Linares, Vladimir Sanchez and Macías, Vicente Eloy Fardales and Rivero, Iraldo Bello},
  title = {Five‐Year Follow‐Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon},
  journal = {Journal of Skin Cancer},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jskc/8852284}
}
Kostenlos starten →